<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Toxicol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Toxicol. Sci</journal-id><journal-id journal-id-type="hwp">toxsci</journal-id><journal-id journal-id-type="publisher-id">toxsci</journal-id><journal-title-group><journal-title>Toxicological Sciences</journal-title></journal-title-group><issn pub-type="ppub">1096-6080</issn><issn pub-type="epub">1096-0929</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24052565</article-id><article-id pub-id-type="pmc">3858199</article-id><article-id pub-id-type="doi">10.1093/toxsci/kft217</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Reactivation of Plasma Butyrylcholinesterase by Pralidoxime Chloride in Patients Poisoned by WHO Class II Toxicity Organophosphorus Insecticides</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="no"><name><surname>Konickx</surname><given-names>Lisa A.</given-names></name><xref ref-type="aff" rid="AF0001">*</xref><xref ref-type="aff" rid="AF0002">&#x02020;</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Worek</surname><given-names>Franz</given-names></name><xref ref-type="aff" rid="AF0003">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Jayamanne</surname><given-names>Shaluka</given-names></name><xref ref-type="aff" rid="AF0004">&#x000a7;</xref><xref ref-type="aff" rid="AF0005">&#x000b6;</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Thiermann</surname><given-names>Horst</given-names></name><xref ref-type="aff" rid="AF0003">&#x02021;</xref></contrib><contrib contrib-type="author" corresp="no"><name><surname>Buckley</surname><given-names>Nicholas A.</given-names></name><xref ref-type="aff" rid="AF0006">||</xref></contrib><contrib contrib-type="author"><name><surname>Eddleston</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="AF0001">*</xref><xref ref-type="aff" rid="AF0005">&#x000b6;</xref><xref ref-type="corresp" rid="c1">
<sup>1</sup>
</xref></contrib><aff id="AF0001">*<institution>Department of Pharmacology, Toxicology, and Therapeutics, University/BHF Centre for Cardiovascular Science, University of Edinburgh</institution>, <addr-line>Edinburgh, EH16 4TJ</addr-line>, <country>UK</country>;</aff><aff id="AF0002">&#x02020;<institution>School of Pharmacy, University of Utrecht</institution>, <addr-line>3508 TC Utrecht</addr-line>, <country>The Netherlands</country>;</aff><aff id="AF0003">&#x02021;<institution>Bundeswehr Institute of Pharmacology and Toxicology</institution>, <addr-line>80937 Munich</addr-line>, <country>Germany</country>;</aff><aff id="AF0004">&#x000a7;<institution>Faculty of Medicine, University of Kelaniya</institution>, <addr-line>Colombo</addr-line>, <country>Sri Lanka</country>;</aff><aff id="AF0005">&#x000b6;<institution>South Asian Clinical Toxicology Research Collaboration, University of Peradeniya</institution>, <country>Sri Lanka</country>; and</aff><aff id="AF0006">||<institution>Medical Professorial Unit, Prince of Wales Hospital Clinical School, University of New South Wales</institution>, <addr-line>Sydney, NSW 2052</addr-line>, <country>Australia</country></aff></contrib-group><author-notes><corresp id="c1"><sup>1</sup>To whom correspondence should be addressed at Department of Pharmacology, Toxicology, and Therapeutics, QMRI E3.20, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK. Fax: <fax>131 242 9215</fax>. E-mail: <email>m.eddleston@ed.ac.uk</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>19</day><month>9</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>19</day><month>9</month><year>2013</year></pub-date><volume>136</volume><issue>2</issue><fpage>274</fpage><lpage>283</lpage><history><date date-type="received"><day>23</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>10</day><month>9</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2013. Published by Oxford University Press on behalf of the Society of Toxicology.</copyright-statement><copyright-year>2013</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by/3.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>Some clinicians assess the efficacy of pralidoxime in organophosphorus (OP) poisoned patients by measuring reactivation of butyrylcholinesterase (BuChE). However, the degree of BuChE inhibition varies by OP insecticide, and it is unclear how well oximes reactivate BuChE <italic>in vivo</italic>. We aimed to assess the usefulness of BuChE activity to monitor pralidoxime treatment by studying its reactivation after pralidoxime administration to patients with laboratory-proven World Health Organization (WHO) class II OP insecticide poisoning. Patient data were derived from 2 studies, a cohort study (using a bolus treatment of 1g pralidoxime chloride) and a randomized controlled trial (RCT) (comparing 2g pralidoxime over 20min, followed by an infusion of 0.5g/h, with placebo). Two grams of pralidoxime variably reactivated BuChE in patients poisoned by 2 diethyl OP insecticides, chlorpyrifos and quinalphos; however, unlike acetylcholinesterase reactivation, this reactivation was not sustained. It did not reactivate BuChE inhibited by the dimethyl OPs dimethoate or fenthion. The 1-g dose produced no reactivation. Pralidoxime produced variable reactivation of BuChE in WHO class II OP-poisoned patients according to the pralidoxime dose administered, OP ingested, and individual patient. The use of BuChE assays for monitoring the effect of pralidoxime treatment is unlikely to be clinically useful.</p></abstract><kwd-group><title>Key Words:</title><kwd>organophosphorus insecticides</kwd><kwd>butyrylcholinest erase</kwd><kwd>pralidoxime</kwd><kwd>marker</kwd><kwd>human poisoning.</kwd></kwd-group><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Organophosphorus (OP) insecticide self-poisoning is a major global health problem (<xref ref-type="bibr" rid="CIT0004">Bertolote <italic>et al.</italic>, 2006</xref>; <xref ref-type="bibr" rid="CIT0023">Jeyaratnam, 1990</xref>), with hundreds of thousands of deaths each year in rural regions of the developing world (<xref ref-type="bibr" rid="CIT0007">Eddleston, 2000</xref>; <xref ref-type="bibr" rid="CIT0020">Gunnell <italic>et al.</italic>, 2007</xref>). Although the more toxic World Health Organization (WHO) class I OPs (those with rat oral LD<sub>50</sub>s of less than 50mg/kg; <xref ref-type="bibr" rid="CIT0037">World Health Organization, 2010</xref>) are being removed from agricultural practice, WHO class II OPs (with rat oral LD<sub>50</sub> of 50mg/kg or more) are still widely used.</p><p content-type="indent">OP insecticides inhibit the enzymes acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase (BuChE, EC 3.1.1.8), although some require metabolism to an oxon form via cytochrome P450 enzymes before becoming active (<xref ref-type="bibr" rid="CIT0028">Lotti, 2001</xref>). Clinical features arise from inhibition of AChE causing overstimulation at cholinergic synapses in the autonomic nervous system, neuromuscular junction, and central nervous system (<xref ref-type="bibr" rid="CIT0003">Ballantyne and Marrs, 1992</xref>). BuChE inhibition, in contrast, appears not to result in clinical features (<xref ref-type="bibr" rid="CIT0003">Ballantyne and Marrs, 1992</xref>; <xref ref-type="bibr" rid="CIT0028">Lotti, 2001</xref>). Management (<xref ref-type="bibr" rid="CIT0008">Eddleston <italic>et al.</italic>, 2008a</xref>; <xref ref-type="bibr" rid="CIT0024">Johnson <italic>et al.</italic>, 2000</xref>) involves resuscitation and the administration of the muscarinic antagonist atropine (<xref ref-type="bibr" rid="CIT0021">Heath and Meredith, 1992</xref>) and an oxime AChE reactivator such as pralidoxime (<xref ref-type="bibr" rid="CIT0016">Eyer, 2003</xref>). The beneficial effects of atropine are clear (<xref ref-type="bibr" rid="CIT0019">Freeman and Epstein, 1955</xref>; <xref ref-type="bibr" rid="CIT0021">Heath and Meredith, 1992</xref>; <xref ref-type="bibr" rid="CIT0024">Johnson <italic>et al.</italic>, 2000</xref>). By contrast, the effect of pralidoxime remains unclear (<xref ref-type="bibr" rid="CIT0005">Buckley <italic>et al.</italic>, 2011</xref>).</p><p content-type="indent">Clinicians have used reactivation of cholinesterase activity in blood as a way of measuring the effect of pralidoxime treatment in poisoned patients. Red-cell AChE assays should be more reliable because clinical effects result from synaptic AChE inhibition, and red-cell AChE has a close kinetic similarity with synaptic AChE. However, assays for BuChE activity are widely available and routinely performed and can be done on routinely sampled plasma samples, whereas AChE assays require whole blood samples that are rapidly cooled (<xref ref-type="bibr" rid="CIT0016">Eyer, 2003</xref>). Therefore, BuChE assays have been used by some physicians to grade severity and to assess reactivation and pralidoxime efficacy (<xref ref-type="bibr" rid="CIT0001">Abdullat <italic>et al.</italic>, 2006</xref>; <xref ref-type="bibr" rid="CIT0025">Khan <italic>et al.</italic>, 2001</xref>; <xref ref-type="bibr" rid="CIT0026">Kwong, 2002</xref>; <xref ref-type="bibr" rid="CIT0027">Lee and Tai, 2001</xref>; <xref ref-type="bibr" rid="CIT0031">Namba <italic>et al.</italic>, 1971</xref>; <xref ref-type="bibr" rid="CIT0032">Pham, 2007</xref>).</p><p content-type="indent">Using BuChE for this purpose is complicated by the variability in BuChE inhibition and perhaps BuChE reactivation by pralidoxime, according to the OP (Eddleston et al., <xref ref-type="bibr" rid="CIT0011">2005</xref>, <xref ref-type="bibr" rid="CIT0012">2008b</xref>). <italic>In vitro</italic> studies have reported mixed results as to whether pralidoxime can reactivate BuChE inhibited by WHO class I OPs (<xref ref-type="bibr" rid="CIT0002">Aurbek <italic>et al.</italic>, 2009</xref>; <xref ref-type="bibr" rid="CIT0022">Jafari and Pourheidari, 2006</xref>; <xref ref-type="bibr" rid="CIT0030">Musilova <italic>et al.</italic>, 2009</xref>). In addition, BuChE becomes aged after inhibition by both diethyl and dimethyl OPs so that it becomes unresponsive to reactivation by pralidoxime (<xref ref-type="bibr" rid="CIT0002">Aurbek <italic>et al.</italic>, 2009</xref>).</p><p content-type="indent">It is, therefore, currently unclear whether measurement of BuChE activity might be appropriate for monitoring pralidoxime treatment in class II OP-poisoned patients. The aim of this study was to examine the reactivation of BuChE <italic>in vivo</italic> after pralidoxime treatment in Sri Lankan patients with laboratory-proven WHO class II OP insecticide poisoning. The data used were derived from 2 published studies: an observational cohort study (<xref ref-type="bibr" rid="CIT0011">Eddleston <italic>et al.</italic>, 2005</xref>) and a randomized controlled trial (RCT) (<xref ref-type="bibr" rid="CIT0010">Eddleston <italic>et al.</italic>, 2009a</xref>) using 2 different regimens of pralidoxime chloride. Analysis of these 2 studies has not previously assessed the effect of pralidoxime on reactivation of BuChE.</p></sec><sec sec-type="materials|methods" id="s2"><title>MATERIALS AND METHODS</title><p>Institutional Review Board approval was received from the Faculty of Medicine Ethics Committee, Colombo, and Oxfordshire Clinical Research Ethics Committee. The RCT was established in response to systematic reviews (<xref ref-type="bibr" rid="CIT0006">Buckley <italic>et al.</italic>, 2005</xref>; <xref ref-type="bibr" rid="CIT0014">Eddleston <italic>et al.</italic>, 2002</xref>) that showed a lack of evidence for pralidoxime effectiveness and has been published in full (<xref ref-type="bibr" rid="CIT0010">Eddleston <italic>et al.</italic>, 2009a</xref>). The results by RCT indicated that pralidoxime was not effective; as a result, pralidoxime was rejected by the WHO&#x02019;s Essential Drugs List (<xref ref-type="bibr" rid="CIT0036">World Health Organization, 2009</xref>), and an updated Cochrane systematic review (<uri xlink:type="simple" xlink:href="http://www.cochrane.org/cochrane-reviews">http://www.cochrane.org/cochrane-reviews</uri>) has reported a lack of evidence for effectiveness (<xref ref-type="bibr" rid="CIT0005">Buckley <italic>et al.</italic>, 2011</xref>).</p><p content-type="indent">Written informed consent was taken from each patient, or their relatives (for patients unconscious or under the age of 16), in their own language.</p><sec id="s3"><title/><sec id="s4"><title/><sec id="s5"><title>Cohort study.</title><p>Patients were identified on admission to 3 Sri Lankan hospitals between March 31, 2002, and May 25, 2004, to observe the difference in clinical features and severity of poisoning for the most common OP insecticides (<xref ref-type="bibr" rid="CIT0011">Eddleston <italic>et al.</italic>, 2005</xref>). The patients received atropine according to a standard protocol (<xref ref-type="bibr" rid="CIT0009">Eddleston <italic>et al.</italic>, 2004</xref>) and pralidoxime chloride as a 1-g bolus followed by further 1-g bolus doses every 6h for 1&#x02013;3 days.</p></sec><sec id="s6"><title>Randomized controlled trial.</title><p>The RCT was conducted in Anuradhapura and Polonnaruwa district hospitals in Sri Lanka from May 26, 2004, until October 18, 2006, to compare the effectiveness of pralidoxime treatment with placebo, in addition to standard therapy, in OP insecticide poisoning (<xref ref-type="bibr" rid="CIT0010">Eddleston <italic>et al.</italic>, 2009a</xref>). Patients were randomized to 2 study arms to receive saline placebo or pralidoxime chloride. Pralidoxime was given as a 2-g loading dose over 20min, followed by an infusion of 0.5g/h until a maximum of 7 days, the patients no longer required atropine, or death.</p><p content-type="indent">For both studies, blood samples were taken from patients before and after pralidoxime administration to measure plasma BuChE activity and pralidoxime and OP insecticide concentrations. Sampling and assays were carried out as described (<xref ref-type="bibr" rid="CIT0016">Eyer, 2003</xref>; <xref ref-type="bibr" rid="CIT0035">Worek <italic>et al.</italic>, 1999</xref>). The mean control AChE and BuChE values in the assay are 586 (SD 5) mU/mmol Hb and 5932 (SD 33) mU/ml, respectively (<xref ref-type="bibr" rid="CIT0035">Worek <italic>et al.</italic>, 1999</xref>). The lower boundary of normal BuChE was set at 3000 mU/ml.</p></sec><sec id="s7"><title>Patient eligibility.</title><p>For this analysis, we included patients from both studies who showed biochemical evidence of cholinergic poisoning (BuChE activity less than 3000 mU/ml) for whom we had proof of the OP ingested and both prepralidoxime and postpralidoxime blood sample analyses. Exclusion criteria were ingestion of more than 1 OP insecticide, incomplete data files, and a different pralidoxime treatment regimen.</p></sec><sec id="s8"><title>Statistical analysis.</title><p>The data analysis was performed in GraphPad Prism (version 5). For both cohort and the RCT, cholinergic activities were summarized with counts (percentages) for categorical variables, and the median (interquartile range [IQR]) for continuous variables, as none were expected to be normally distributed. BuChE activity at baseline for each agent was compared using the Kruskal-Wallis test. BuChE reactivation from baseline to 1h postpralidoxime was assessed overall and for each agent using a 2-sided paired <italic>t</italic> test and reported as the difference (95% confidence interval [CI] of the difference). (Due to the relatively small size of the sample, tests of normality were not performed. Sensitivity analyses using the nonparametric equivalent of the paired <italic>t</italic> test showed no substantial difference.)</p></sec></sec></sec></sec><sec id="s9"><title>RESULTS</title><p>Patients were selected from the 2 study databases. Of the 802 patients in the published cohort study, only 157 had BuChE measurements performed (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Ninety-three patients met the inclusion criteria (<xref ref-type="table" rid="T1">Tables 1</xref> and <xref ref-type="table" rid="T2">2</xref>). The RCT randomized 235 patients, of whom 168 met the inclusion criteria for this study. Ninety-six patients were treated with pralidoxime and 72 with placebo (<xref ref-type="table" rid="T1">Tables 1</xref> and <xref ref-type="table" rid="T2">2</xref>).</p><fig fig-type="figure" id="F1" position="float"><label>FIG. 1.</label><caption><p>Flow diagram of progress through cohort and RCT data. Abbreviations: BuChE, butyrylcholinesterase; RCT, randomized controlled trial.</p></caption><graphic xlink:href="toxsci_kft217_f0001"/></fig><table-wrap id="T1" position="float"><label>TABLE 1</label><caption><p>Distribution of OP Insecticide Ingested by Each Patient</p></caption><table frame="vsides" rules="groups"><thead><tr><th align="left" rowspan="2" valign="bottom" colspan="1">Number</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cohort</th><th align="center" valign="bottom" rowspan="1" colspan="1">RCT Pralidoxime</th><th align="center" valign="bottom" rowspan="1" colspan="1">RCT Placebo</th></tr><tr><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic> = 93</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic> = 96</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic>n</italic> = 72</th></tr></thead><tbody><tr><td colspan="4" rowspan="1">Organophosphorus insecticide ingested, <italic>n</italic> (%)</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Chlorpyrifos</td><td align="center" rowspan="1" colspan="1">71 (76.3)</td><td align="center" rowspan="1" colspan="1">51 (53.1)</td><td align="center" rowspan="1" colspan="1">35 (48.6)</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Quinalphos</td><td align="center" rowspan="1" colspan="1">5 (5.4)</td><td align="center" rowspan="1" colspan="1">5 (5.2)</td><td align="center" rowspan="1" colspan="1">5 (6.9)</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dimethoate</td><td align="center" rowspan="1" colspan="1">9 (9.7)</td><td align="center" rowspan="1" colspan="1">23 (23.9)</td><td align="center" rowspan="1" colspan="1">13 (18.1)</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Fenthion</td><td align="center" rowspan="1" colspan="1">4 (4.3)</td><td align="center" rowspan="1" colspan="1">9 (9.4)</td><td align="center" rowspan="1" colspan="1">10 (13.9)</td></tr><tr><td rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Others<sup><italic>a</italic></sup>
</td><td align="center" rowspan="1" colspan="1">4 (4.3)</td><td align="center" rowspan="1" colspan="1">8 (8.3)</td><td align="center" rowspan="1" colspan="1">9 (12.5)</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>
<sup><italic>a</italic></sup>Other organophosphoruses insecticides included: phenthoate, diazinon, and profenofos.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>TABLE 2</label><caption><p>Admission Characteristics of Patients Included in the Analysis</p></caption><table frame="vsides" rules="groups"><thead><tr><th colspan="2" valign="bottom" rowspan="1">
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Cohort</th><th align="center" valign="bottom" rowspan="1" colspan="1">RCT Pralidoxime</th><th align="center" valign="bottom" rowspan="1" colspan="1">RCT Placebo</th></tr></thead><tbody><tr><td colspan="2" rowspan="1">Time since ingestion, h; <italic>n</italic>
</td><td align="center" rowspan="1" colspan="1">3.8 (2.3&#x02013;5.5); <italic>n</italic> = 91</td><td align="center" rowspan="1" colspan="1">4.7 (3.3&#x02013;8); <italic>n</italic> = 86</td><td align="center" rowspan="1" colspan="1">4.2 (3&#x02013;6.8); <italic>n</italic> = 71</td></tr><tr><td colspan="2" rowspan="1">AChE activity on admission, (mU/&#x000b5;mol Hb); <italic>n</italic>
</td><td align="center" rowspan="1" colspan="1">107 (32&#x02013;196); <italic>n</italic> = 72</td><td align="center" rowspan="1" colspan="1">34 (11&#x02013;68); <italic>n</italic> = 81</td><td align="center" rowspan="1" colspan="1">33 (7&#x02013;52); <italic>n</italic> = 64</td></tr><tr><td rowspan="6" colspan="1">BuChE activity on admission, (mU/ml); <italic>n</italic>
</td><td rowspan="1" colspan="1">All patients</td><td align="center" rowspan="1" colspan="1">121 (31&#x02013;343); <italic>n</italic> = 92</td><td align="center" rowspan="1" colspan="1">35 (0&#x02013;36); <italic>n</italic> = 89</td><td align="center" rowspan="1" colspan="1">23 (0&#x02013;166); <italic>n</italic> = 71</td></tr><tr><td rowspan="1" colspan="1">Chlorpyrifos</td><td align="center" rowspan="1" colspan="1">121 (45&#x02013;319); <italic>n</italic> = 70</td><td align="center" rowspan="1" colspan="1">10 (0&#x02013;74); <italic>n</italic> = 45</td><td align="center" rowspan="1" colspan="1">20 (0&#x02013;133); <italic>n</italic> = 34</td></tr><tr><td rowspan="1" colspan="1">Quinalphos</td><td align="center" rowspan="1" colspan="1">11 (6&#x02013;82); <italic>n</italic> = 5</td><td align="center" rowspan="1" colspan="1">10 (0&#x02013;1149); <italic>n</italic> = 5</td><td align="center" rowspan="1" colspan="1">10 (5&#x02013;350); <italic>n</italic> = 5</td></tr><tr><td rowspan="1" colspan="1">Dimethoate</td><td align="center" rowspan="1" colspan="1">1245 (501&#x02013;1754); <italic>n</italic> = 9</td><td align="center" rowspan="1" colspan="1">534 (130&#x02013;1099); <italic>n</italic> = 23</td><td align="center" rowspan="1" colspan="1">783 (294&#x02013;1556); <italic>n</italic> = 13</td></tr><tr><td rowspan="1" colspan="1">Fenthion</td><td align="center" rowspan="1" colspan="1">10 (4&#x02013;25); <italic>n</italic> = 4</td><td align="center" rowspan="1" colspan="1">10 (3&#x02013;79); <italic>n</italic> = 8</td><td align="center" rowspan="1" colspan="1">1 (0&#x02013;24); <italic>n</italic> = 10</td></tr><tr><td rowspan="1" colspan="1">Others<sup><italic>a</italic></sup>
</td><td align="center" rowspan="1" colspan="1">124 (35&#x02013;228); <italic>n</italic> = 4</td><td align="center" rowspan="1" colspan="1">415 (3&#x02013;1072); <italic>n</italic> = 8</td><td align="center" rowspan="1" colspan="1">35 (5-1344); <italic>n</italic> = 9</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>Data are median (interquartile range). Data were collected on admission to hospital; recruitment occurred soon after. Data were not available for all patients.</p></fn><fn fn-type="other"><p>Abbreviations: AChE, acetylcholinesterase; BuChE, butyrylcholinesterase; <italic>n</italic>, numbers of cases on which the analysis is based.</p></fn><fn fn-type="other"><p>
<sup><italic>a</italic></sup>Other organophosphoruses insecticides included: phenthoate, diazinon, and profenofos.</p></fn></table-wrap-foot></table-wrap><sec id="s10"><title/><sec id="s11"><title>BuChE Activity on Admission</title><p>For patients in both cohort and RCT, there were differences in BuChE activity on admission (<italic>p</italic> &#x0003c; .001). Patients with chlorpyrifos poisoning had substantially lower BuChE activity than dimethoate-poisoned patients (<xref ref-type="table" rid="T2">Table 2</xref>) (<italic>p</italic> &#x0003c; .001). This finding has been previously reported (<xref ref-type="bibr" rid="CIT0012">Eddleston <italic>et al.</italic>, 2008b</xref>). Although the number of patients taking fenthion and quinalphos was small, both insecticides also inhibited BuChE to a significantly greater extent than dimethoate (<xref ref-type="table" rid="T2">Table 2</xref>; <italic>p</italic> = .002 and <italic>p</italic> &#x0003c; .001, respectively).</p></sec><sec id="s12"><title>Pralidoxime Regimens and AChE Activity</title><p>The pralidoxime regimen used in the RCT (2g loading dose over 20min, followed by a steady infusion of 0.5g/h) produced a measured peak plasma pralidoxime concentration of 250 &#x000b5;mol/l at 1h and a steady state concentration around 100 &#x000b5;mol/l (<xref ref-type="bibr" rid="CIT0010">Eddleston <italic>et al.</italic>, 2009a</xref>). Plasma concentrations were not measured in the cohort study due to the intermittent pralidoxime administration. However, the much more rapid bolus administration of 1g in this study (typically over &#x0003c; 1min) would have produced a higher peak pralidoxime concentration, than the 2-g loading dose, that would have rapidly decreased over time (half-life usually &#x0003c; 1h).</p><p content-type="indent">Both regimens reactivated AChE (<xref ref-type="fig" rid="F2">Figs. 2A</xref> and <xref ref-type="fig" rid="F3">3A</xref>) as previously reported (Eddleston <italic>et al.</italic>, <xref ref-type="bibr" rid="CIT0011">2005</xref>, <xref ref-type="bibr" rid="CIT0010">2009a</xref>). Pralidoxime 1 and 2g (followed by 0.5g/h) increased mean AChE activity at 1h by 139 (95% CI 94&#x02013;184, <italic>p</italic> &#x0003c; .001) and 170 (95% CI 134&#x02013;205, <italic>p</italic> &#x0003c; .001) mU/&#x000b5;mol Hb, respectively.</p><fig fig-type="figure" id="F2" position="float"><label>FIG. 2.</label><caption><p>AChE and BuChE activity in poisoned patients receiving bolus pralidoxime (1g bolus every 6 hrs for 24 hrs after admission) (median with interquartile range [IQR]). A, AChE activity for the cohort study patients included in this analysis; B&#x02013;F: BuChE activities with B, all patients; C, chlorpyrifos; D, quinalphos; E, dimethoate; F, fenthion poisoning. Time = 0 is the time of first pralidoxime administration. Abbreviations: AChE, acetylcholinesterase; BuChE, butyrylcholinesterase. </p></caption><graphic xlink:href="toxsci_kft217_f0002"/></fig><fig fig-type="figure" id="F3" position="float"><label>FIG. 3.</label><caption><p>AChE and BuChE activity in poisoned patients receiving pralidoxime by infusion (2g loading dose over 20min followed by 0.5mg/h; circle) or placebo (square) (median with IQR). A, AChE activity for the RCT patients included in this analysis; B&#x02013;F: BuChE activities with B, all patients; C, chlorpyrifos; D, quinalphos; E, dimethoate; F, fenthion poisoning. Time = 0 is time of first pralidoxime administration. Abbreviations: AChE, acetylcholinesterase; BuChE, butyrylcholinesterase.</p></caption><graphic xlink:href="toxsci_kft217_f0003"/></fig></sec><sec id="s13"><title>Effect of Pralidoxime on BuChE Activity</title><p>Assessing the total population of cohort patients, treatment with pralidoxime 1g bolus produced no reactivation of BuChE activity at 1h (<xref ref-type="fig" rid="F2">Fig. 2B</xref>; mean difference 55 mU/ml [95% CI &#x02212;64 to 174, <italic>p</italic> = .36]). Further 6 hourly bolus doses had no apparent effect over the first 24h. Assessing individual OP insecticides, BuChE activity nonsignificantly decreased in dimethoate-poisoned patients in the first hour (<xref ref-type="fig" rid="F2">Fig. 2E</xref>, mean difference &#x02212;59 mU/ml [95% CI &#x02212;395 to 278, <italic>p</italic> = .69]). No significant reactivation occurred in chlorpyrifos (<xref ref-type="fig" rid="F2">Fig. 2C</xref>, mean difference 50 mU/ml [95% CI &#x02212;96 to 195, <italic>p</italic> = .50]), quinalphos (<xref ref-type="fig" rid="F2">Fig. 2D</xref>; mean difference 338 mU/ml [95% CI &#x02212;567 to 1244, <italic>p</italic> = .36]), or fenthion (<xref ref-type="fig" rid="F2">Fig. 2F</xref>; mean difference 5 mU/ml [95% CI &#x02212;25 to 34, <italic>p</italic> = .66]) poisoned patients.</p><p content-type="indent">Assessing the total population of RCT patients receiving pralidoxime of 2g loading dose over 20min, followed by 0.5mg/h, BuChE over the first hour was significantly reactivated (<xref ref-type="fig" rid="F3">Fig. 3B</xref>, mean difference 416 mU/ml [95% CI 262 to 571, <italic>p</italic> &#x0003c; .001]). The difference was maximal at 1h and decreased up to 48h as BuChE became re-inhibited. This re-inhibition of BuChE&#x02014;despite the steady infusion of pralidoxime&#x02014;was quite different from that seen with AChE, which remained activated after initial reactivation with this dose of pralidoxime (<xref ref-type="fig" rid="F3">Fig. 3A</xref>).</p><p content-type="indent">BuChE reactivation occurred almost entirely in patients poisoned with diethyl OP insecticides, because reactivation was absent in dimethoate-poisoned (<xref ref-type="fig" rid="F3">Fig. 3E</xref>, mean difference 22 mU/ml [95% CI &#x02212;142 to 186, <italic>p</italic> = .79]) and fenthion-poisoned (<xref ref-type="fig" rid="F3">Fig. 3F</xref>, mean difference 0 mU/ml [95% CI &#x02212;59 to 58, <italic>p</italic> = .99]) patients. The level of BuChE reactivation was small in chlorpyrifos-poisoned patients (to 17% of the lower limit of normal, <xref ref-type="fig" rid="F3">Fig. 3C</xref>; mean difference 513 mU/ml [95% CI 310 to 716, <italic>p</italic> &#x0003c; .001]), whereas reactivation in quinalphos-poisoned patients was nonsignificantly greater (to 36% of the lower limit of normal, <xref ref-type="fig" rid="F3">Fig. 3D</xref>; mean difference 1076 mU/ml [95% CI &#x02212;320 to 2472, <italic>p</italic> = .10]).</p></sec><sec id="s14"><title>Variability by Patient</title><p>Looking at individual patients, marked variability occurred within the general pattern of responsiveness to pralidoxime in patients receiving the higher RCT dose (<xref ref-type="fig" rid="F4">Figs. 4</xref>&#x02013;<xref ref-type="fig" rid="F6">6</xref>). For example, some patients poisoned by chlorpyrifos showed increases of greater than 2500 mU/ml at 1h, whereas others showed further inhibition (<xref ref-type="fig" rid="F5">Fig 5A</xref>). This variability persisted over several days for the 2 most common OP insecticides, chlorpyrifos and dimethoate, with and without pralidoxime (<xref ref-type="fig" rid="F6">Fig. 6</xref>).</p><fig fig-type="figure" id="F4" position="float"><label>FIG. 4.</label><caption><p>Change in BuChE activity over the first hour from start of pralidoxime treatment in pralidoxime-treated patients in the RCT (2g loading dose over 20min, followed by 0.5g/h) plotted against time since poisoning. The 2 values from each patient are linked with a line. A, all patients; B, chlorpyrifos; C, quinalphos; D, dimethoate; E, fenthion-poisoned patients. Abbreviations: Pam, patients receiving pralidoxime; Plac, patients receiving placebo; BuChE, butyrylcholinesterase; RCT, randomized controlled trial.</p></caption><graphic xlink:href="toxsci_kft217_f0004"/></fig><fig fig-type="figure" id="F5" position="float"><label>FIG. 5.</label><caption><p>Change in BuChE activity over the first hour from start of pralidoxime treatment in pralidoxime-treated patients in the RCT (2g loading dose over 20min, followed by 0.5g/h). A, change in BuChE for each patient, ordered by size and OP ingested; B, plot of BuChE activity change versus time since ingestion; C, plot of BuChE activity change versus BuChE activity on admission. Chlorpyrifos (circle), quinalphos (diamond), dimethoate (square), and fenthion (triangle). Abbreviations: BuChE, butyrylcholinesterase; OP organophosphorus; RCT, randomized controlled trial.</p></caption><graphic xlink:href="toxsci_kft217_f0005"/></fig><fig fig-type="figure" id="F6" position="float"><label>FIG. 6.</label><caption><p>Change in BuChE activity for each RCT patient over time, for the two most common OPs. A, chlorpyrifos with pralidoxime; B, chlorpyrifos with placebo; C, dimethoate with pralidoxime; and D, dimethoate with placebo. Median and IQR are shown by the thick line. Abbreviations: BuChE, butyrylcholinesterase; IQR, interquartile range; RCT, randomized controlled trial.</p></caption><graphic xlink:href="toxsci_kft217_f0006"/></fig><p content-type="indent">The relationship between BuChE reactivation in the first hour and delay to pralidoxime administration postpoisoning or BuChE activity at time of pralidoxime administration was assessed for each OP insecticide. With chlorpyrifos, as expected, reactivation at 1h was inversely related to time since poisoning (<xref ref-type="fig" rid="F4">Figs. 4B</xref> and <xref ref-type="fig" rid="F5">5B</xref>). For the other OPs, no such relation was apparent although there were few patients with quinalphos or fenthion poisoning. No relationship between BuChE activity at pralidoxime administration and BuChE reactivation at 1h was found (<xref ref-type="fig" rid="F5">Fig. 5C</xref>).</p></sec></sec></sec><sec id="s15"><title>DISCUSSION</title><p>In this study, we have shown that a bolus of pralidoxime chloride 1g does not reactivate BuChE inhibited by WHO class II OPs. In contrast, a 2-g loading dose over 20min, followed by a steady infusion of 0.5mg/h, reactivated diethyl OP-inhibited BuChE although this was not sustained. No reactivation occurred of dimethyl OP-inhibited BuChE. There was marked variation between individuals in how they responded to pralidoxime. These findings extend the results of these previously published cohort and RCT.</p><p content-type="indent">BuChE reactivation has been used as a marker of pralidoxime dosing and therefore efficacy in OP-poisoned patients. However, BuChE inhibition is not relevant to the pathophysiology of OP poisoning, and its usefulness would need to be linked to either clinical features or an association with AChE inhibition (if AChE is a good marker, see below). BuChE activity is not closely linked to severity in some forms of OP poisoning, eg, BuChE can be close to zero in patients with few clinical signs following chlorpyrifos poisoning (<xref ref-type="bibr" rid="CIT0012">Eddleston <italic>et al.</italic>, 2008b</xref>).</p><p content-type="indent">This study shows that BuChE activity after pralidoxime therapy does not closely correlate with AChE activity. BuChE reactivation is much less than AChE reactivation and is not sustained by pralidoxime infusions. AChE activity has been recommended as a useful marker of pralidoxime function (<xref ref-type="bibr" rid="CIT0034">Thiermann <italic>et al.</italic>, 2010</xref>). However, recently, several findings have produced doubts about the usefulness of AChE as a marker for WHO class II OP insecticides (<xref ref-type="bibr" rid="CIT0018">Eyer <italic>et al.</italic>, 2010</xref>)&#x02014;a lack of clinical benefit despite clear reactivation of AChE in an RCT (<xref ref-type="bibr" rid="CIT0010">Eddleston <italic>et al.</italic>, 2009a</xref>), a lack of correlation with severity in profenofos poisoning (<xref ref-type="bibr" rid="CIT0015">Eddleston <italic>et al.</italic>, 2009b</xref>), and a lack of correlation with clinical features in a pig model of dimethoate pesticide poisoning (<xref ref-type="bibr" rid="CIT0013">Eddleston <italic>et al.</italic>, 2012</xref>). It is likely to be better to use a clinical marker (such as neurophysiological tests of neuromuscular junction function) than a biochemical marker to follow pralidoxime (or other forms of oxime) efficacy (<xref ref-type="bibr" rid="CIT0034">Thiermann <italic>et al.</italic>, 2010</xref>).</p><p content-type="indent">We did not measure BuChE aging in these samples. In spite of the decrease in reactivation when the time since ingestion increased, no correlation was found. In addition, it is unlikely that aging was responsible for the very poor reactivation in most patients because the <italic>in vitro</italic> half-life of aging of human BuChE for dimethylated and diethylated enzyme, respectively, is about 3 and 9h (<xref ref-type="bibr" rid="CIT0002">Aurbek <italic>et al.</italic>, 2009</xref>) and the median time to presentation of these patients was 3&#x02013;5h. This would suggest that a median of 50% of BuChE would be available for reactivation with dimethyl OP-poisoned patients and more than this for diethyl OP-poisoned patients.</p><p content-type="indent">
<italic>In vitro</italic> studies have been done to measure the reactivation of BuChE by pralidoxime for WHO class I and II OP poisonings. <xref ref-type="bibr" rid="CIT0022">Jafari and Pourheidari (2006)</xref> showed that pralidoxime 100&#x003bc;M reversed human BuChE inhibition by parathion and by paraoxon by about 50%. <xref ref-type="bibr" rid="CIT0033">Rotenberg <italic>et al.</italic> (1995)</xref> showed that obidoxime (175 &#x000b5;g/ml) reactivated BuChE inhibited by chlorpyrifos by 70% and parathion by 90%. In contrast, other <italic>in vitro</italic> studies have shown that neither pralidoxime nor obidoxime can usefully reactivate BuChE inhibited by paraoxon, parathion, or methyl parathion (<xref ref-type="bibr" rid="CIT0002">Aurbek <italic>et al.</italic>, 2009</xref>; <xref ref-type="bibr" rid="CIT0030">Musilova <italic>et al.</italic>, 2009</xref>). Due to these findings, <xref ref-type="bibr" rid="CIT0002">Aurbek <italic>et al.</italic> (2009)</xref> concluded that BuChE activity was inappropriate for monitoring the efficacy of standard doses of pralidoxime after WHO class I OP poisoning.</p><p content-type="indent">BuChE assays can be useful for OP poisoning because they may indicate likely exposure and be used to monitor the elimination of the OP (<xref ref-type="bibr" rid="CIT0008">Eddleston <italic>et al.</italic>, 2008a</xref>; <xref ref-type="bibr" rid="CIT0026">Kwong, 2002</xref>). The liver synthesizes and secretes BuChE continuously; hence, an increase in BuChE activity may indicate the absence of an inhibiting OP in the circulation and the end of a cholinergic crisis (<xref ref-type="bibr" rid="CIT0029">Mason, 2000</xref>). This may explain the rise in BuChE activity in patients poisoned by dimethoate (an OP that is rapidly eliminated) after 48h. AChE assays would not be a good marker of OP elimination because reproduction of AChE will occur by erythropoiesis, a slow process with a regeneration of less than 1% AChE of normal each day. Cholinesterase status after OP poisoning is best established by measuring AChE and BuChE activities, re-activatability, and inhibitory activity (a marker of active anticholinesterase in the sample; <xref ref-type="bibr" rid="CIT0016">Eyer, 2003</xref>; <xref ref-type="bibr" rid="CIT0016">Eyer <italic>et al.</italic>, 2003</xref>).</p><p content-type="indent">In summary, we show that pralidoxime-induced reactivation of BuChE is highly variable, according to the dose, OP involved, and the individual poisoned. This indicates that BuChE assays are not useful for monitoring the effect of pralidoxime treatment <italic>in vivo</italic> for poisoning with WHO class II OP insecticides.</p></sec><sec id="s16"><title>FUNDING</title><p>
<funding-source>Wellcome Trust</funding-source> (<award-id>063560</award-id>); <funding-source>Chief Scientist Office &#x00026; Scottish Funding Council (Senior Research Fellowship); Wellcome Trust/National Health and Medical Research Council International Collaborative Research Award</funding-source> (<award-id>071669</award-id>).</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors wish to thank the directors, consultant physicians, and medical and nursing staff of the study hospitals for their support; Renate Heilmair and Elisabeth Topoll for technical assistance; and the Oxford-Colombo Collaboration and SACTRC study doctors and coordinators for their immensely valuable work. ME is a Scottish Senior Clinical Fellow (funded by the Chief Scientist Office and Scottish Funding Council) and a Lister Research Prize Fellow.</p></ack><ref-list><title>REFERENCES</title><ref id="CIT0001"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abdullat</surname><given-names>I. M.</given-names></name><name><surname>Battah</surname><given-names>A. H.</given-names></name><name><surname>Hadidi</surname><given-names>K. A</given-names></name></person-group>
<year>(2006)</year>
<article-title>The use of serial measurement of plasma cholinesterase in the management of acute poisoning with organophosphates and carbamates</article-title>.
<source>Forensic Sci. Int</source>.
<volume>162</volume>, <fpage>126</fpage>&#x02013;<lpage>130</lpage><pub-id pub-id-type="pmid">16890390</pub-id></mixed-citation></ref><ref id="CIT0002"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aurbek</surname><given-names>N.</given-names></name><name><surname>Thiermann</surname><given-names>H.</given-names></name><name><surname>Eyer</surname><given-names>F.</given-names></name><name><surname>Eyer</surname><given-names>P.</given-names></name><name><surname>Worek</surname><given-names>F</given-names></name></person-group>
<year>(2009)</year>
<article-title>Suitability of human butyrylcholinesterase as therapeutic marker and pseudo catalytic scavenger in organophosphate poisoning: A kinetic analysis</article-title>.
<source>Toxicology</source>
<volume>259</volume>, <fpage>133</fpage>&#x02013;<lpage>139</lpage><pub-id pub-id-type="pmid">19428953</pub-id></mixed-citation></ref><ref id="CIT0003"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Ballantyne</surname><given-names>B.</given-names></name><name><surname>Marrs</surname><given-names>T. C</given-names></name></person-group>
<year>(1992)</year>
<article-title>Overview of the biological and clinical aspects of organophosphates and carbamates.</article-title> In <source>Clinical and Experimental Toxicology of Organophosphates and Carbamates</source> (<person-group person-group-type="editor"><name><surname>Ballantyne</surname><given-names>B.</given-names></name><name><surname>Marrs</surname><given-names>T. C.</given-names></name></person-group>, Eds.), pp. <fpage>3</fpage>&#x02013;<lpage>14</lpage>
<publisher-name>Butterworth heinemann</publisher-name>, <publisher-loc>Oxford</publisher-loc></mixed-citation></ref><ref id="CIT0004"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bertolote</surname><given-names>J. M.</given-names></name><name><surname>Fleischmann</surname><given-names>A.</given-names></name><name><surname>Eddleston</surname><given-names>M.</given-names></name><name><surname>Gunnell</surname><given-names>D</given-names></name></person-group>
<year>(2006)</year>
<article-title>Deaths from pesticide poisoning: A global response</article-title>.
<source>Brit. J. Psychiat</source>.
<volume>189</volume>, <fpage>201</fpage>&#x02013;<lpage>203</lpage></mixed-citation></ref><ref id="CIT0005"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buckley</surname><given-names>N. A.</given-names></name><name><surname>Eddleston</surname><given-names>M.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Bevan</surname><given-names>M.</given-names></name><name><surname>Robertson</surname><given-names>J</given-names></name></person-group>
<year>(2011)</year>
<article-title>Oximes for acute organophosphate pesticide poisoning</article-title>.
<source>Cochrane Database. Syst. Rev</source>.
<volume>2</volume>, <fpage>CD005085</fpage><pub-id pub-id-type="pmid">21328273</pub-id></mixed-citation></ref><ref id="CIT0006"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buckley</surname><given-names>N. A.</given-names></name><name><surname>Eddleston</surname><given-names>M.</given-names></name><name><surname>Szinicz</surname><given-names>L</given-names></name></person-group>
<year>(2005)</year>
<article-title>Oximes for acute organophosphate pesticide poisoning</article-title>.
<source>Cochrane Database Syst. Rev.</source>
<volume>1</volume>, <fpage>CD005085</fpage><pub-id pub-id-type="pmid">15654704</pub-id></mixed-citation></ref><ref id="CIT0007"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eddleston</surname><given-names>M</given-names></name></person-group>
<year>(2000)</year>
<article-title>Patterns and problems of deliberate self-poisoning in the developing world</article-title>.
<source>Q. J. Med</source>.
<volume>93</volume>, <fpage>715</fpage>&#x02013;<lpage>731</lpage></mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eddleston</surname><given-names>M.</given-names></name><name><surname>Buckley</surname><given-names>N. A.</given-names></name><name><surname>Eyer</surname><given-names>P.</given-names></name><name><surname>Dawson</surname><given-names>A. H</given-names></name></person-group>
<year>(2008a)</year>
<article-title>Medical management of acute organophosphorus pesticide poisoning</article-title>.
<source>Lancet</source>
<volume>371</volume>, <fpage>597</fpage>&#x02013;<lpage>607</lpage><pub-id pub-id-type="pmid">17706760</pub-id></mixed-citation></ref><ref id="CIT0009"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eddleston</surname><given-names>M.</given-names></name><name><surname>Dawson</surname><given-names>A.</given-names></name><name><surname>Karalliedde</surname><given-names>L.</given-names></name><name><surname>Dissanayake</surname><given-names>W.</given-names></name><name><surname>Hittarage</surname><given-names>A.</given-names></name><name><surname>Azher</surname><given-names>S.</given-names></name><name><surname>Buckley</surname><given-names>N. A</given-names></name></person-group>
<year>(2004)</year>
<article-title>Early management after self-poisoning with an organophosphorus or carbamate pesticide&#x02014;A treatment protocol for junior doctors</article-title>.
<source>Crit. Care</source>
<volume>8</volume>, <fpage>R391</fpage>&#x02013;<lpage>R397</lpage><pub-id pub-id-type="pmid">15566582</pub-id></mixed-citation></ref><ref id="CIT0010"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eddleston</surname><given-names>M.</given-names></name><name><surname>Eyer</surname><given-names>P.</given-names></name><name><surname>Worek</surname><given-names>F.</given-names></name><name><surname>Juszczak</surname><given-names>E.</given-names></name><name><surname>Alder</surname><given-names>N.</given-names></name><name><surname>Mohamed</surname><given-names>F.</given-names></name><name><surname>Senarathna</surname><given-names>L.</given-names></name><name><surname>Hittarage</surname><given-names>A.</given-names></name><name><surname>Azher</surname><given-names>S.</given-names></name><name><surname>Jeganathan</surname><given-names>K.</given-names></name><etal/></person-group>
<year>(2009a)</year>
<article-title>Pralidoxime in acute organophosphorus insecticide poisoning&#x02014;A randomised controlled trial</article-title>.
<source>PLoS Med</source>.
<volume>6</volume>, <fpage>e1000104</fpage><pub-id pub-id-type="pmid">19564902</pub-id></mixed-citation></ref><ref id="CIT0011"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eddleston</surname><given-names>M.</given-names></name><name><surname>Eyer</surname><given-names>P.</given-names></name><name><surname>Worek</surname><given-names>F.</given-names></name><name><surname>Mohamed</surname><given-names>F.</given-names></name><name><surname>Senarathna</surname><given-names>L.</given-names></name><name><surname>von Meyer</surname><given-names>L.</given-names></name><name><surname>Juszczak</surname><given-names>E.</given-names></name><name><surname>Hittarage</surname><given-names>A.</given-names></name><name><surname>Azhar</surname><given-names>S.</given-names></name><name><surname>Dissanayake</surname><given-names>W.</given-names></name><etal/></person-group>
<year>(2005)</year>
<article-title>Differences between organophosphorus insecticides in human self-poisoning: A prospective cohort study</article-title>.
<source>Lancet</source>
<volume>366</volume>, <fpage>1452</fpage>&#x02013;<lpage>1459</lpage><pub-id pub-id-type="pmid">16243090</pub-id></mixed-citation></ref><ref id="CIT0012"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eddleston</surname><given-names>M.</given-names></name><name><surname>Eyer</surname><given-names>P.</given-names></name><name><surname>Worek</surname><given-names>F.</given-names></name><name><surname>Sheriff</surname><given-names>M. H. R.</given-names></name><name><surname>Buckley</surname><given-names>N. A</given-names></name></person-group>
<year>(2008b)</year>
<article-title>Predicting outcome using butyrylcholinesterase activity in organophosphorus pesticide self-poisoning</article-title>.
<source>QJM</source>.
<volume>101</volume>, <fpage>467</fpage>&#x02013;<lpage>474</lpage><pub-id pub-id-type="pmid">18375477</pub-id></mixed-citation></ref><ref id="CIT0013"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eddleston</surname><given-names>M.</given-names></name><name><surname>Street</surname><given-names>J. M.</given-names></name><name><surname>Self</surname><given-names>I.</given-names></name><name><surname>Thompson</surname><given-names>A.</given-names></name><name><surname>King</surname><given-names>T.</given-names></name><name><surname>Williams</surname><given-names>N.</given-names></name><name><surname>Naredo</surname><given-names>G.</given-names></name><name><surname>Yu</surname><given-names>L.-M.</given-names></name><name><surname>Dissanayake</surname><given-names>K. N.</given-names></name><name><surname>Worek</surname><given-names>F.</given-names></name><etal/></person-group>
<year>(2012)</year>
<article-title>A role for solvents in the toxicity of agricultural organophosphorus pesticides</article-title>.
<source>Toxicology</source>
<volume>294</volume>, <fpage>94</fpage>&#x02013;<lpage>103</lpage><pub-id pub-id-type="pmid">22365945</pub-id></mixed-citation></ref><ref id="CIT0014"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eddleston</surname><given-names>M.</given-names></name><name><surname>Szinicz</surname><given-names>L.</given-names></name><name><surname>Eyer</surname><given-names>P.</given-names></name><name><surname>Buckley</surname><given-names>N</given-names></name></person-group>
<year>(2002)</year>
<article-title>Oximes in acute organophosphorus pesticide poisoning: A systematic review of clinical trials</article-title>.
<source>QJM</source>.
<volume>95</volume>, <fpage>275</fpage>&#x02013;<lpage>283</lpage><pub-id pub-id-type="pmid">11978898</pub-id></mixed-citation></ref><ref id="CIT0015"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eddleston</surname><given-names>M.</given-names></name><name><surname>Worek</surname><given-names>F.</given-names></name><name><surname>Eyer</surname><given-names>P.</given-names></name><name><surname>Thiermann</surname><given-names>H.</given-names></name><name><surname>von Meyer</surname><given-names>L.</given-names></name><name><surname>Jeganathan</surname><given-names>K.</given-names></name><name><surname>Sheriff</surname><given-names>M. H.</given-names></name><name><surname>Dawson</surname><given-names>A. H.</given-names></name><name><surname>Buckley</surname><given-names>N. A</given-names></name></person-group>
<year>(2009b)</year>
<article-title>Poisoning with the S-Alkyl organophosphorus insecticides profenofos and prothiofos</article-title>.
<source>QJM</source>.
<volume>102</volume>, <fpage>785</fpage>&#x02013;<lpage>792</lpage><pub-id pub-id-type="pmid">19737786</pub-id></mixed-citation></ref><ref id="CIT0016"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eyer</surname><given-names>F.</given-names></name><name><surname>Meischner</surname><given-names>V.</given-names></name><name><surname>Kiderlen</surname><given-names>D.</given-names></name><name><surname>Thiermann</surname><given-names>H.</given-names></name><name><surname>Worek</surname><given-names>F.</given-names></name><name><surname>Haberkorn</surname><given-names>M.</given-names></name><name><surname>Felgenhauer</surname><given-names>N.</given-names></name><name><surname>Zilker</surname><given-names>T.</given-names></name><name><surname>Eyer</surname><given-names>P</given-names></name></person-group>
<year>(2003)</year>
<article-title>Human parathion poisoning. A toxicokinetic analysis</article-title>.
<source>Toxicol. Rev</source>.
<volume>22</volume>, <fpage>143</fpage>&#x02013;<lpage>163</lpage><pub-id pub-id-type="pmid">15181664</pub-id></mixed-citation></ref><ref id="CIT0017"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eyer</surname><given-names>P</given-names></name></person-group>
<year>(2003)</year>
<article-title>The role of oximes in the management of organophosphorus pesticide poisoning</article-title>.
<source>Toxicol. Rev</source>.
<volume>22</volume>, <fpage>165</fpage>&#x02013;<lpage>190</lpage><pub-id pub-id-type="pmid">15181665</pub-id></mixed-citation></ref><ref id="CIT0018"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Eyer</surname><given-names>P.</given-names></name><name><surname>Worek</surname><given-names>F.</given-names></name><name><surname>Thiermann</surname><given-names>H.</given-names></name><name><surname>Eddleston</surname><given-names>M</given-names></name></person-group>
<year>(2010)</year>
<article-title>Paradox findings may challenge orthodox reasoning in acute organophosphate poisoning</article-title>.
<source>Chem. Biol. Interact</source>.
<volume>187</volume>, <fpage>270</fpage>&#x02013;<lpage>278</lpage><pub-id pub-id-type="pmid">19883634</pub-id></mixed-citation></ref><ref id="CIT0019"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Freeman</surname><given-names>G.</given-names></name><name><surname>Epstein</surname><given-names>M. A</given-names></name></person-group>
<year>(1955)</year>
<article-title>Therapeutic factors in survival after lethal cholinesterase inhibition by phosphorus pesticides</article-title>.
<source>N. Engl. J. Med</source>.
<volume>253</volume>, <fpage>266</fpage>&#x02013;<lpage>271</lpage><pub-id pub-id-type="pmid">13244813</pub-id></mixed-citation></ref><ref id="CIT0020"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gunnell</surname><given-names>D.</given-names></name><name><surname>Eddleston</surname><given-names>M.</given-names></name><name><surname>Phillips</surname><given-names>M. R.</given-names></name><name><surname>Konradsen</surname><given-names>F</given-names></name></person-group>
<year>(2007)</year>
<article-title>The global distribution of fatal pesticide self-poisoning: Systematic review</article-title>.
<source>BMC Public Health</source>
<volume>7</volume>, <fpage>357</fpage><pub-id pub-id-type="pmid">18154668</pub-id></mixed-citation></ref><ref id="CIT0021"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Heath</surname><given-names>A. J. W.</given-names></name><name><surname>Meredith</surname><given-names>T</given-names></name></person-group>
<year>(1992)</year>
<article-title>Atropine in the management of anticholinesterase poisoning.</article-title> In <source>Clinical and Experimental Toxicology of Organophosphates and Carbamates</source> (<person-group person-group-type="editor"><name><surname>Ballantyne</surname><given-names>B.</given-names></name><name><surname>Marrs</surname><given-names>T.</given-names></name></person-group>, Eds.), pp. <fpage>543</fpage>&#x02013;<lpage>554</lpage>
<publisher-name>Butterworth Heinemann</publisher-name>, <publisher-loc>Oxford</publisher-loc></mixed-citation></ref><ref id="CIT0022"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jafari</surname><given-names>M.</given-names></name><name><surname>Pourheidari</surname><given-names>G</given-names></name></person-group>
<year>(2006)</year>
<article-title>The reactivation effect of pralidoxime in human blood on parathion and paraoxon-induced cholinesterase inhibition</article-title>.
<source>DARU J. Pharm. Sci</source>.
<volume>14</volume>, <fpage>37</fpage>&#x02013;<lpage>43</lpage></mixed-citation></ref><ref id="CIT0023"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jeyaratnam</surname><given-names>J</given-names></name></person-group>
<year>(1990)</year>
<article-title>Acute pesticide poisoning: A major global health problem</article-title>.
<source>World Health Stat. Q</source>.
<volume>43</volume>, <fpage>139</fpage>&#x02013;<lpage>144</lpage><pub-id pub-id-type="pmid">2238694</pub-id></mixed-citation></ref><ref id="CIT0024"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnson</surname><given-names>M. K.</given-names></name><name><surname>Jacobsen</surname><given-names>D.</given-names></name><name><surname>Meredith</surname><given-names>T. J.</given-names></name><name><surname>Eyer</surname><given-names>P.</given-names></name><name><surname>Heath</surname><given-names>A. J. W.</given-names></name><name><surname>Ligtenstein</surname><given-names>D. A.</given-names></name><name><surname>Marrs</surname><given-names>T. C.</given-names></name><name><surname>Szinicz</surname><given-names>L.</given-names></name><name><surname>Vale</surname><given-names>J. A.</given-names></name><name><surname>Haines</surname><given-names>J. A</given-names></name></person-group>
<year>(2000)</year>
<article-title>Evaluation of antidotes for poisoning by organophosphorus pesticides</article-title>.
<source>Emerg. Med</source>.
<volume>12</volume>, <fpage>22</fpage>&#x02013;<lpage>37</lpage></mixed-citation></ref><ref id="CIT0025"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Hemalatha</surname><given-names>R.</given-names></name><name><surname>Jeyaseelan</surname><given-names>L.</given-names></name><name><surname>Oommen</surname><given-names>A.</given-names></name><name><surname>Zachariah</surname><given-names>A</given-names></name></person-group>
<year>(2001)</year>
<article-title>Neuroparalysis and oxime efficacy in organophosphate poisoning: A study of butyrylcholinesterase</article-title>.
<source>Hum. Exp. Toxicol</source>.
<volume>20</volume>, <fpage>169</fpage>&#x02013;<lpage>174</lpage><pub-id pub-id-type="pmid">11393267</pub-id></mixed-citation></ref><ref id="CIT0026"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kwong</surname><given-names>T. C</given-names></name></person-group>
<year>(2002)</year>
<article-title>Organophosphate pesticides: Biochemistry and clinical toxicology</article-title>.
<source>Ther. Drug Monit</source>.
<volume>24</volume>, <fpage>144</fpage>&#x02013;<lpage>149</lpage><pub-id pub-id-type="pmid">11805735</pub-id></mixed-citation></ref><ref id="CIT0027"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>P.</given-names></name><name><surname>Tai</surname><given-names>D. Y. H</given-names></name></person-group>
<year>(2001)</year>
<article-title>Clinical features of patients with organophosphate poisoning requiring intensive care</article-title>.
<source>Intensive Care Med</source>.
<volume>27</volume>, <fpage>694</fpage>&#x02013;<lpage>699</lpage><pub-id pub-id-type="pmid">11398695</pub-id></mixed-citation></ref><ref id="CIT0028"><mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Lotti</surname><given-names>M</given-names></name></person-group>
<year>(2001)</year>
<article-title>Clinical toxicology of anticholinesterase agents in humans.</article-title> In <source>Handbook of Pesticide Toxicology. Volume 2. Agents</source> (<person-group person-group-type="editor"><name><surname>Krieger</surname><given-names>R.I.</given-names></name><name><surname>Doull</surname><given-names>J.</given-names></name></person-group>, Eds.), <edition>2 ed.</edition>, pp. <fpage>1043</fpage>&#x02013;<lpage>1085</lpage>
<publisher-name>Academic Press</publisher-name>, <publisher-loc>San Diego, CA</publisher-loc></mixed-citation></ref><ref id="CIT0029"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mason</surname><given-names>H. J</given-names></name></person-group>
<year>(2000)</year>
<article-title>The recovery of plasma cholinesterase and erythrocyte acetylcholinesterase activity in workers after over-exposure to dichlorvos</article-title>.
<source>Occup. Med. (London)</source>
<volume>50</volume>, <fpage>343</fpage>&#x02013;<lpage>347</lpage><pub-id pub-id-type="pmid">10975133</pub-id></mixed-citation></ref><ref id="CIT0030"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Musilova</surname><given-names>L.</given-names></name><name><surname>Kuca</surname><given-names>K.</given-names></name><name><surname>Jung</surname><given-names>Y. S.</given-names></name><name><surname>Jun</surname><given-names>D</given-names></name></person-group>
<year>(2009)</year>
<article-title>In vitro oxime-assisted reactivation of paraoxon-inhibited human acetylcholinesterase and butyrylcholinesterase</article-title>.
<source>Clin. Toxicol. (Phila)</source>
<volume>47</volume>, <fpage>545</fpage>&#x02013;<lpage>550</lpage><pub-id pub-id-type="pmid">19586353</pub-id></mixed-citation></ref><ref id="CIT0031"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Namba</surname><given-names>T.</given-names></name><name><surname>Nolte</surname><given-names>C.</given-names></name><name><surname>Jackrel</surname><given-names>J.</given-names></name><name><surname>Grob</surname><given-names>D</given-names></name></person-group>
<year>(1971)</year>
<article-title>Poisoning due to organophosphate insecticides</article-title>.
<source>Am. J. Med</source>.
<volume>50</volume>, <fpage>475</fpage>&#x02013;<lpage>492</lpage><pub-id pub-id-type="pmid">4324629</pub-id></mixed-citation></ref><ref id="CIT0032"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pham</surname><given-names>D</given-names></name></person-group>
<year>(2007)</year>
<article-title>The change of plasma cholinesterase in acute organophosphate poisoning patients</article-title>.
<source>Asia Pacific Association of Medical Toxicology Congress</source> (Abstract 27).</mixed-citation></ref><ref id="CIT0033"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rotenberg</surname><given-names>M.</given-names></name><name><surname>Shefi</surname><given-names>M.</given-names></name><name><surname>Dany</surname><given-names>S.</given-names></name><name><surname>Dore</surname><given-names>I.</given-names></name><name><surname>Tirosh</surname><given-names>M.</given-names></name><name><surname>Almog</surname><given-names>S</given-names></name></person-group>
<year>(1995)</year>
<article-title>Differentiation between organophosphate and carbamate poisoning</article-title>.
<source>Clin. Chim. Acta</source>
<volume>234</volume>, <fpage>11</fpage>&#x02013;<lpage>21</lpage><pub-id pub-id-type="pmid">7758210</pub-id></mixed-citation></ref><ref id="CIT0034"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Thiermann</surname><given-names>H.</given-names></name><name><surname>Seeger</surname><given-names>T.</given-names></name><name><surname>Gonder</surname><given-names>S.</given-names></name><name><surname>Herkert</surname><given-names>N.</given-names></name><name><surname>Antkowiak</surname><given-names>B.</given-names></name><name><surname>Zilker</surname><given-names>T.</given-names></name><name><surname>Eyer</surname><given-names>F.</given-names></name><name><surname>Worek</surname><given-names>F</given-names></name></person-group>
<year>(2010)</year>
<article-title>Assessment of neuromuscular dysfunction during poisoning by organophosphorus compounds</article-title>.
<source>Chem. Biol. Interact</source>.
<volume>187</volume>, <fpage>265</fpage>&#x02013;<lpage>269</lpage><pub-id pub-id-type="pmid">20036651</pub-id></mixed-citation></ref><ref id="CIT0035"><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Worek</surname><given-names>F.</given-names></name><name><surname>Mast</surname><given-names>U.</given-names></name><name><surname>Kiderlen</surname><given-names>D.</given-names></name><name><surname>Diepold</surname><given-names>C.</given-names></name><name><surname>Eyer</surname><given-names>P</given-names></name></person-group>
<year>(1999)</year>
<article-title>Improved determination of acetylcholinesterase activity in human whole blood</article-title>.
<source>Clin. Chim. Acta</source>
<volume>288</volume>, <fpage>73</fpage>&#x02013;<lpage>90</lpage><pub-id pub-id-type="pmid">10529460</pub-id></mixed-citation></ref><ref id="CIT0036"><mixed-citation publication-type="book">
<collab>World Health Organization</collab>
<year>(2009)</year>
<article-title>The Selection and Use of Essential Medicines. Report of the WHO Expert Committee, 2009 (including the 16th WHO Model List of Essential Medicines and the 2nd WHO Model List of Essential Medicines for Children)</article-title> (Technical Report Series 958). <publisher-name>World Health Organization</publisher-name>, <publisher-loc>Geneva</publisher-loc></mixed-citation></ref><ref id="CIT0037"><mixed-citation publication-type="book">
<collab>World Health Organization</collab>
<year>(2010)</year>
<source>The WHO Recommended Classification of Pesticides by Hazard and Guidelines to Classification: 2009</source>.
<publisher-name>World Health Organization</publisher-name>, <publisher-loc>Geneva</publisher-loc></mixed-citation></ref></ref-list></back></article>